In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Medexus Pharmaceuticals Inc (MDP – Research Report). Medexus Pharmaceuticals Inc (TSX: MDP), the Healthcare company has received a rating update from a Wall Street analyst on November 10.
According to TipRanks.com, PhD is a 5-star analyst with an average return of 17.8% and a 43.5% success rate. PhD covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Repare Therapeutics, and Greenbrook Tms.
Medexus Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of C$3.71, an 85.5% upside from current levels. In a report issued on November 9, Canaccord Genuity also upgraded the stock to Buy with a C$3.75 price target.
Based on Medexus Pharmaceuticals Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of C$31.56 million and net profit of C$651K. In comparison, last year the company earned revenue of C$23.05 million and had a GAAP net loss of C$48K.
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
The company’s shares closed last Friday at C$1.85.
